US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Ketamine Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-050-05 D-0635-2023
Class II · Moderate risk Ongoing

FentaNYL 50 mcg/mL

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-910-25 D-0634-2023
Class II · Moderate risk Ongoing

Succinylcholine Cl Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-020-05 D-0633-2023
Class II · Moderate risk Ongoing

PHENYLephrine HCl Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC D-0632-2023
Class II · Moderate risk Terminated

Famotidine Tablets

Reason Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg.

Glenmark Therapeutics, Inc. NDC 72657-113-20 D-0939-2023
Class II · Moderate risk Ongoing

Pyrazinamide

Reason CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

RemedyRepack Inc. NDC 70518-2534-01 D-0578-2023
Class II · Moderate risk Ongoing

Ketotifen Fumarate 0.025 %

Reason CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

RemedyRepack Inc. NDC 70518-1142-00 D-0577-2023
Class II · Moderate risk Terminated

LORazepam Injection

Reason CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

RemedyRepack Inc. NDC 17478-0040-01 D-0576-2023
Class II · Moderate risk Terminated

HyperLyte CR Injection

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8094-2 D-0755-2023
Class II · Moderate risk Terminated

HyperLyte CR Injection

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8094-1 D-0754-2023
Class II · Moderate risk Terminated

Lidocaine 2% HCl Inj

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8091-1 D-0753-2023
Class II · Moderate risk Terminated

Potassium Acetate Injection

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8078-1 D-0752-2023
Class II · Moderate risk Terminated

Sodium Phosphates Injection 4 mEq/3 mMol/mL

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8077-1 D-0751-2023
Class II · Moderate risk Terminated

Msa 7.84% Msg 8.56%

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-8029-1 D-0750-2023
Class II · Moderate risk Terminated

vasopressin 50 units added to 0.9% sodium chloride 50 mL*

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-9002-1 D-0749-2023